vTv Therapeutics Inc.
NASDAQ:VTVT · NASDAQ Capital Market
+$1.18 today
Vol 0.07M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-41.9%
avg 30.0%
ROIC
-39.4%
avg -337.0%
ROA
-30.0%
avg -79.6%
Analysis
ROA is currently the strongest return metric at -30.0% versus its period average of -79.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul J. Sekhri | Chief Executive Officer, President & Chairman of the Board | $1.04M | — | 68 | $392,212.00 | 14.99% |
Michael Steven Tung | Executive Vice President & Chief Financial Officer | $595,728.00 | — | 52 | $89,969.00 | 3.44% |
Barry Brown | Chief Accounting Officer | $311,977.00 | — | 65 | $0.00 | <0.01% |
Richard S. Nelson | Executive Vice President of Corporate Development & Director | $201,081.00 | — | 56 | $10.39M | 396.84% |
Carmen Valcarce | Chief Scientific Officer & Executive Vice President | — | — | — | — | — |
Thomas Strack | Chief Medical Officer | — | — | — | — | — |
Martin Lafontaine | Chief Commercial Officer | — | — | — | — | — |
Elizabeth Keiley | Executive Vice President & General Counsel | — | — | 60 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -42.7% | +50.3% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -42.7% over three years. Forward estimates point to Revenue at +50.3% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
OS Therapies Incorporated
AMEX:OSTX
$75.71M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
Spruce Biosciences, Inc.
NASDAQ:SPRB
$71.19M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$66.38M
MiNK Therapeutics, Inc.
NASDAQ:INKT
$59.88M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$50.19M
CervoMed Inc.
CRVO
$22.68M
Werewolf Therapeutics, Inc.
HOWL
$18.52M
IO Biotech, Inc.
IOBT
$885,690.00
Who manages VTVT?
vTv Therapeutics Inc. (VTVT) lists 8 active executives. The top listed executive is Carmen Valcarce, Chief Scientific Officer & Executive Vice President.
Are VTVT insiders buying or selling?
Recent insider activity shows net buying of $86.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.